Greg Reyes

Greg Reyes, MD, PhD was elected to our board November 2020. Dr. Reyes brings 35 years experience in biotech and large pharma to Artelo. Past leadership positions include overseeing Drug Discovery at Celgene, leading the Oncology franchise at Biogen Idec, heading Discovery Biology at the Pfizer’s Ann Arbor campus and leading Tumor Biology and Infectious Diseases at Schering-Plough Research Institute. His teams have progressed over 50 small molecules and biologics from discovery into preclinical and clinical development. One compound, developed under his preclinical leadership, was Victrelis™ (boceprevir) approved as one of the first small molecule antiviral treatments for chronic hepatitis C. This seminal work led to the 2012 Prix Galien Award shared by Victrelis™ and Vertex’s Incivek™ as the ‘best pharmaceutical agent’ in both the UK and US.

Dr. Reyes obtained his MD and PhD at The Johns Hopkins School of Medicine, trained in medicine at Stanford University Hospital, and was awarded a Damon Runyon Cancer Research Fellowship for studies at Stanford’s Cancer Biology Research Lab. He has nearly 100 scientific publications and 50 US and foreign patents and applications. Dr. Reyes currently serves as advisor to Cancer Research UK’s New Agents Committee and previously served on NIH’s National Advisory General Medical Sciences Council, and the Standing Review Committee for the Research Centers in Minority Institutions, National Center for Research Resources.